Global Campylobacteriosis Market

Campylobacteriosis Comprehensive Study by Application (Hospitals, Clinics, Private Laboratories, Independent Physician Chambers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Diagnosis (Culture-based Diagnosis, Rapid Detection Tests (Immunological, Molecular, and Other )), End User (Animals (Cattle, Sheep, Chickens, Turkeys, Dogs, Cats, Mink, Ferrets, and Others), Humans) Players and Region - Global Market Outlook to 2028

Campylobacteriosis Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Campylobacteriosis Market Scope
Campylobacteriosis is caused by a bacteria called Campylobacter jejuni, which is found worldwide in the intestinal tracts of animals. The bacteria are spiral-shaped and can cause disease in animals and humans. Most cases of campylobacteriosis are associated with handling or eating raw or undercooked poultry meat. Campylobacteriosis causes gastrointestinal symptoms, such as diarrhea, cramping, abdominal pain, and fever in domestic animals and humans. Young animals and humans are the most severely affected. This has projected the growth of the global campylobacteriosis treatment market in the forecast period.



The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Campylobacteriosis market throughout the predicted period.

Meridian Bioscience, Inc. (United States), Becton, Dickinson and Company (United States), Siemens Healthineers (Germany), BIOTECON Diagnostics (Germany), Agilent Technologies (United States), Thermo Fisher Scientific (United States), Alere Inc. (United States), QIAGEN (Germany), Roche Molecular Systems, Inc. (United States), Lonza (Switzerland), ZeptoMetrix (United States) and Sequenom (United States) are some of the key players that are part of study coverage.

Segmentation Overview
The study have segmented the market of Global Campylobacteriosis market , by Application (Hospitals, Clinics, Private Laboratories, Independent Physician Chambers and Others) and Region with country level break-up.

On the basis of geography, the market of Campylobacteriosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Rising Clinical Research Studies for Campylobacteriosis Diagnosis

Market Growth Drivers:
Increasing Number of Humans, which Affected with Campylobacteriosis Infection and Growing Infection in Animals across the Worldwide

Challenges:
Strict Government Regulations

Restraints:
Lack of Awareness About Campylobacteriosis Infection

Opportunities:
Increasing Research and Development Activities Focused on Campylobacteriosis and Rising Purchasing Power of Developing Countries

In January 2018, TECHLAB Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance for the CAMPYLOBACTER QUIK CHEK and the CAMPYLOBACTER CHEK tests. Both are intended to aid the diagnosis of campylobacteriosis, one of the most common causes of diarrheal illness in the United States.
WHO is working towards the strengthening of food safety systems in an increasingly globalized world. Setting international food safety standards, enhancing disease surveillance, educating consumers, and training food handlers in safe food handling are amongst the most critical interventions in the prevention of foodborne illnesses.

Key Target Audience
Campylobacteriosis Drugs Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Private Laboratories
  • Independent Physician Chambers
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
  • Others

By Diagnosis
  • Culture-based Diagnosis
  • Rapid Detection Tests (Immunological, Molecular, and Other )

By End User
  • Animals (Cattle, Sheep, Chickens, Turkeys, Dogs, Cats, Mink, Ferrets, and Others)
  • Humans

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Humans, which Affected with Campylobacteriosis Infection
      • 3.2.2. Growing Infection in Animals across the Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Strict Government Regulations
    • 3.4. Market Trends
      • 3.4.1. Rising Clinical Research Studies for Campylobacteriosis Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Campylobacteriosis, by Application, Distribution Channel, Diagnosis, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Campylobacteriosis (Value)
      • 5.2.1. Global Campylobacteriosis by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Private Laboratories
        • 5.2.1.4. Independent Physician Chambers
        • 5.2.1.5. Others
      • 5.2.2. Global Campylobacteriosis by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Online
        • 5.2.2.4. Others
      • 5.2.3. Global Campylobacteriosis by: Diagnosis (Value)
        • 5.2.3.1. Culture-based Diagnosis
        • 5.2.3.2. Rapid Detection Tests (Immunological, Molecular, and Other )
      • 5.2.4. Global Campylobacteriosis by: End User (Value)
        • 5.2.4.1. Animals (Cattle, Sheep, Chickens, Turkeys, Dogs, Cats, Mink, Ferrets, and Others)
        • 5.2.4.2. Humans
      • 5.2.5. Global Campylobacteriosis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Campylobacteriosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Meridian Bioscience, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens Healthineers (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BIOTECON Diagnostics (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Agilent Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fisher Scientific (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alere Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. QIAGEN (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Roche Molecular Systems, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lonza (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ZeptoMetrix (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sequenom (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Campylobacteriosis Sale, by Application, Distribution Channel, Diagnosis, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Campylobacteriosis (Value)
      • 7.2.1. Global Campylobacteriosis by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Private Laboratories
        • 7.2.1.4. Independent Physician Chambers
        • 7.2.1.5. Others
      • 7.2.2. Global Campylobacteriosis by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Online
        • 7.2.2.4. Others
      • 7.2.3. Global Campylobacteriosis by: Diagnosis (Value)
        • 7.2.3.1. Culture-based Diagnosis
        • 7.2.3.2. Rapid Detection Tests (Immunological, Molecular, and Other )
      • 7.2.4. Global Campylobacteriosis by: End User (Value)
        • 7.2.4.1. Animals (Cattle, Sheep, Chickens, Turkeys, Dogs, Cats, Mink, Ferrets, and Others)
        • 7.2.4.2. Humans
      • 7.2.5. Global Campylobacteriosis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Campylobacteriosis: by Application(USD Million)
  • Table 2. Campylobacteriosis Hospitals , by Region USD Million (2017-2022)
  • Table 3. Campylobacteriosis Clinics , by Region USD Million (2017-2022)
  • Table 4. Campylobacteriosis Private Laboratories , by Region USD Million (2017-2022)
  • Table 5. Campylobacteriosis Independent Physician Chambers , by Region USD Million (2017-2022)
  • Table 6. Campylobacteriosis Others , by Region USD Million (2017-2022)
  • Table 7. Campylobacteriosis: by Distribution Channel(USD Million)
  • Table 8. Campylobacteriosis Hospital Pharmacy , by Region USD Million (2017-2022)
  • Table 9. Campylobacteriosis Retail Pharmacy , by Region USD Million (2017-2022)
  • Table 10. Campylobacteriosis Online , by Region USD Million (2017-2022)
  • Table 11. Campylobacteriosis Others , by Region USD Million (2017-2022)
  • Table 12. Campylobacteriosis: by Diagnosis(USD Million)
  • Table 13. Campylobacteriosis Culture-based Diagnosis , by Region USD Million (2017-2022)
  • Table 14. Campylobacteriosis Rapid Detection Tests (Immunological, Molecular, and Other ) , by Region USD Million (2017-2022)
  • Table 15. Campylobacteriosis: by End User(USD Million)
  • Table 16. Campylobacteriosis Animals (Cattle, Sheep, Chickens, Turkeys, Dogs, Cats, Mink, Ferrets, and Others) , by Region USD Million (2017-2022)
  • Table 17. Campylobacteriosis Humans , by Region USD Million (2017-2022)
  • Table 18. South America Campylobacteriosis, by Country USD Million (2017-2022)
  • Table 19. South America Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 20. South America Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 21. South America Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 22. South America Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 23. Brazil Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 24. Brazil Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 25. Brazil Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 26. Brazil Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 27. Argentina Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 28. Argentina Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 29. Argentina Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 30. Argentina Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 31. Rest of South America Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 32. Rest of South America Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 34. Rest of South America Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 35. Asia Pacific Campylobacteriosis, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 37. Asia Pacific Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 38. Asia Pacific Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 39. Asia Pacific Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 40. China Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 41. China Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 42. China Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 43. China Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 44. Japan Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 45. Japan Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 46. Japan Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 47. Japan Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 48. India Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 49. India Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 50. India Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 51. India Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 52. South Korea Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 53. South Korea Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 54. South Korea Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 55. South Korea Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 56. Taiwan Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 57. Taiwan Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 58. Taiwan Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 59. Taiwan Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 60. Australia Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 61. Australia Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 62. Australia Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 63. Australia Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 68. Europe Campylobacteriosis, by Country USD Million (2017-2022)
  • Table 69. Europe Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 70. Europe Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 71. Europe Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 72. Europe Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 73. Germany Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 74. Germany Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 75. Germany Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 76. Germany Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 77. France Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 78. France Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 79. France Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 80. France Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 81. Italy Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 82. Italy Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 83. Italy Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 84. Italy Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 85. United Kingdom Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 86. United Kingdom Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 87. United Kingdom Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 88. United Kingdom Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 89. Netherlands Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 90. Netherlands Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 91. Netherlands Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 92. Netherlands Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 93. Rest of Europe Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 94. Rest of Europe Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 95. Rest of Europe Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 96. Rest of Europe Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 97. MEA Campylobacteriosis, by Country USD Million (2017-2022)
  • Table 98. MEA Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 99. MEA Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 100. MEA Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 101. MEA Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 102. Middle East Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 103. Middle East Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 104. Middle East Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 105. Middle East Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 106. Africa Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 107. Africa Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 108. Africa Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 109. Africa Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 110. North America Campylobacteriosis, by Country USD Million (2017-2022)
  • Table 111. North America Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 112. North America Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 113. North America Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 114. North America Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 115. United States Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 116. United States Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 117. United States Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 118. United States Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 119. Canada Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 120. Canada Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 121. Canada Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 122. Canada Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 123. Mexico Campylobacteriosis, by Application USD Million (2017-2022)
  • Table 124. Mexico Campylobacteriosis, by Distribution Channel USD Million (2017-2022)
  • Table 125. Mexico Campylobacteriosis, by Diagnosis USD Million (2017-2022)
  • Table 126. Mexico Campylobacteriosis, by End User USD Million (2017-2022)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Campylobacteriosis: by Application(USD Million)
  • Table 140. Campylobacteriosis Hospitals , by Region USD Million (2023-2028)
  • Table 141. Campylobacteriosis Clinics , by Region USD Million (2023-2028)
  • Table 142. Campylobacteriosis Private Laboratories , by Region USD Million (2023-2028)
  • Table 143. Campylobacteriosis Independent Physician Chambers , by Region USD Million (2023-2028)
  • Table 144. Campylobacteriosis Others , by Region USD Million (2023-2028)
  • Table 145. Campylobacteriosis: by Distribution Channel(USD Million)
  • Table 146. Campylobacteriosis Hospital Pharmacy , by Region USD Million (2023-2028)
  • Table 147. Campylobacteriosis Retail Pharmacy , by Region USD Million (2023-2028)
  • Table 148. Campylobacteriosis Online , by Region USD Million (2023-2028)
  • Table 149. Campylobacteriosis Others , by Region USD Million (2023-2028)
  • Table 150. Campylobacteriosis: by Diagnosis(USD Million)
  • Table 151. Campylobacteriosis Culture-based Diagnosis , by Region USD Million (2023-2028)
  • Table 152. Campylobacteriosis Rapid Detection Tests (Immunological, Molecular, and Other ) , by Region USD Million (2023-2028)
  • Table 153. Campylobacteriosis: by End User(USD Million)
  • Table 154. Campylobacteriosis Animals (Cattle, Sheep, Chickens, Turkeys, Dogs, Cats, Mink, Ferrets, and Others) , by Region USD Million (2023-2028)
  • Table 155. Campylobacteriosis Humans , by Region USD Million (2023-2028)
  • Table 156. South America Campylobacteriosis, by Country USD Million (2023-2028)
  • Table 157. South America Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 158. South America Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 159. South America Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 160. South America Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 161. Brazil Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 162. Brazil Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 163. Brazil Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 164. Brazil Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 165. Argentina Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 166. Argentina Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 167. Argentina Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 168. Argentina Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 169. Rest of South America Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 170. Rest of South America Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 171. Rest of South America Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 172. Rest of South America Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 173. Asia Pacific Campylobacteriosis, by Country USD Million (2023-2028)
  • Table 174. Asia Pacific Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 175. Asia Pacific Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 176. Asia Pacific Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 177. Asia Pacific Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 178. China Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 179. China Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 180. China Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 181. China Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 182. Japan Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 183. Japan Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 184. Japan Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 185. Japan Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 186. India Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 187. India Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 188. India Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 189. India Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 190. South Korea Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 191. South Korea Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 192. South Korea Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 193. South Korea Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 194. Taiwan Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 195. Taiwan Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 196. Taiwan Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 197. Taiwan Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 198. Australia Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 199. Australia Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 200. Australia Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 201. Australia Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 206. Europe Campylobacteriosis, by Country USD Million (2023-2028)
  • Table 207. Europe Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 208. Europe Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 209. Europe Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 210. Europe Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 211. Germany Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 212. Germany Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 213. Germany Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 214. Germany Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 215. France Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 216. France Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 217. France Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 218. France Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 219. Italy Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 220. Italy Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 221. Italy Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 222. Italy Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 223. United Kingdom Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 224. United Kingdom Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 225. United Kingdom Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 226. United Kingdom Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 227. Netherlands Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 228. Netherlands Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 229. Netherlands Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 230. Netherlands Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 231. Rest of Europe Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 232. Rest of Europe Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 233. Rest of Europe Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 234. Rest of Europe Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 235. MEA Campylobacteriosis, by Country USD Million (2023-2028)
  • Table 236. MEA Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 237. MEA Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 238. MEA Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 239. MEA Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 240. Middle East Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 241. Middle East Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 242. Middle East Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 243. Middle East Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 244. Africa Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 245. Africa Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 246. Africa Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 247. Africa Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 248. North America Campylobacteriosis, by Country USD Million (2023-2028)
  • Table 249. North America Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 250. North America Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 251. North America Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 252. North America Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 253. United States Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 254. United States Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 255. United States Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 256. United States Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 257. Canada Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 258. Canada Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 259. Canada Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 260. Canada Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 261. Mexico Campylobacteriosis, by Application USD Million (2023-2028)
  • Table 262. Mexico Campylobacteriosis, by Distribution Channel USD Million (2023-2028)
  • Table 263. Mexico Campylobacteriosis, by Diagnosis USD Million (2023-2028)
  • Table 264. Mexico Campylobacteriosis, by End User USD Million (2023-2028)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Campylobacteriosis: by Application USD Million (2017-2022)
  • Figure 5. Global Campylobacteriosis: by Distribution Channel USD Million (2017-2022)
  • Figure 6. Global Campylobacteriosis: by Diagnosis USD Million (2017-2022)
  • Figure 7. Global Campylobacteriosis: by End User USD Million (2017-2022)
  • Figure 8. South America Campylobacteriosis Share (%), by Country
  • Figure 9. Asia Pacific Campylobacteriosis Share (%), by Country
  • Figure 10. Europe Campylobacteriosis Share (%), by Country
  • Figure 11. MEA Campylobacteriosis Share (%), by Country
  • Figure 12. North America Campylobacteriosis Share (%), by Country
  • Figure 13. Global Campylobacteriosis share by Players 2022 (%)
  • Figure 14. Global Campylobacteriosis share by Players (Top 3) 2022(%)
  • Figure 15. Global Campylobacteriosis share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Meridian Bioscience, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Meridian Bioscience, Inc. (United States) Revenue: by Geography 2022
  • Figure 19. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Becton, Dickinson and Company (United States) Revenue: by Geography 2022
  • Figure 21. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Siemens Healthineers (Germany) Revenue: by Geography 2022
  • Figure 23. BIOTECON Diagnostics (Germany) Revenue, Net Income and Gross profit
  • Figure 24. BIOTECON Diagnostics (Germany) Revenue: by Geography 2022
  • Figure 25. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 26. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 27. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 28. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 29. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Alere Inc. (United States) Revenue: by Geography 2022
  • Figure 31. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 32. QIAGEN (Germany) Revenue: by Geography 2022
  • Figure 33. Roche Molecular Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Roche Molecular Systems, Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Lonza (Switzerland) Revenue: by Geography 2022
  • Figure 37. ZeptoMetrix (United States) Revenue, Net Income and Gross profit
  • Figure 38. ZeptoMetrix (United States) Revenue: by Geography 2022
  • Figure 39. Sequenom (United States) Revenue, Net Income and Gross profit
  • Figure 40. Sequenom (United States) Revenue: by Geography 2022
  • Figure 41. Global Campylobacteriosis: by Application USD Million (2023-2028)
  • Figure 42. Global Campylobacteriosis: by Distribution Channel USD Million (2023-2028)
  • Figure 43. Global Campylobacteriosis: by Diagnosis USD Million (2023-2028)
  • Figure 44. Global Campylobacteriosis: by End User USD Million (2023-2028)
  • Figure 45. South America Campylobacteriosis Share (%), by Country
  • Figure 46. Asia Pacific Campylobacteriosis Share (%), by Country
  • Figure 47. Europe Campylobacteriosis Share (%), by Country
  • Figure 48. MEA Campylobacteriosis Share (%), by Country
  • Figure 49. North America Campylobacteriosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Meridian Bioscience, Inc. (United States)
  • Becton, Dickinson and Company (United States)
  • Siemens Healthineers (Germany)
  • BIOTECON Diagnostics (Germany)
  • Agilent Technologies (United States)
  • Thermo Fisher Scientific (United States)
  • Alere Inc. (United States)
  • QIAGEN (Germany)
  • Roche Molecular Systems, Inc. (United States)
  • Lonza (Switzerland)
  • ZeptoMetrix (United States)
  • Sequenom (United States)
Select User Access Type

Key Highlights of Report


May 2023 204 Pages 63 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Campylobacteriosis Market Quantitative research analysis
Global Campylobacteriosis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Campylobacteriosis study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Campylobacteriosis Market is gaining popularity and expected to see strong valuation by 2028 .
According to AMA, the Global Campylobacteriosis market is expected to see growth rate of xx%.
The Campylobacteriosis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Campylobacteriosis Market Report?

Have a Query? Click Here

Other Related Reports

Bronchiolitis Comprehensive Study by Type (Viral Bronchiolitis, Bronchiolitis Obliterans), Treatment (Flu Shot, Corticosteroids, Intravenous Fluid Treatment, Others), End-users (Hospitals, Clinics, O...
$ 3650
Bacterial Meningitis Comprehensive Study by Type (Pneumococcal meningitis, Meningococcal meningitis, Listeria monocytogenes meningitis, Neonatal meningitis, Hemophilus (Hib) meningitis), Treatment (A...
$ 3750
Burkholderia Cepacia Infection Comprehensive Study by Application (Kids, Adults), Drug Type (Trimethoprim, Sulfamethoxazole, Trimethoprim and sulfamethoxazole, Meropenem, Minocycline, Cefepime, Tigec...
$ 3650
Transitional Cell Carcinoma Comprehensive Study by Application (Hospitals, Cancer Palliative care clinics, Diagnostic centers, Pharmacies), Drug (Levatinib, Atezolizumab, Nivelumab, Enzalutamide, Abi...
$ 3750
Balantidiasis Comprehensive Study by Type (Tetracycline, Iodoquinol, Metronidazole, Others), Application (Hospitals, Diagnostic Centers, Clinics, Others) Players and Region - Global Market Outlook to...
$ 3500
Transverse Myelitis Comprehensive Study by Therapy (Physical therapy, Occupational therapy, Psychotherapy), Treatment (Intravenous steroids, Plasma exchange therapy, Antiviral medication, Pain medica...
$ 3750